MR GENTLE:比较酰化胃饥饿素在接受血管内取栓的前循环缺血性卒中患者中的多中心随机对照2期试验
该研究为研究者发起的2期随机开放标签盲法终点试验,计划纳入80例接受血管内取栓且取栓前NIHSS评分≥10分的前循环缺血性卒中患者,比较静脉酰化胃饥饿素600µg每日两次连用5天联合标准治疗与单纯标准治疗的疗效与安全性。主要结局为第7天NIHSS评分(校正取栓前NIHSS及其他基线特征),次要结局包括第3天MRI梗死体积、不良事件及90天功能恢复。
要点
- 拟纳入80例取栓前NIHSS≥10分的前循环缺血性卒中患者。
- 酰化胃饥饿素600µg每日两次静脉给药5天,症状发作6小时内启动。
- 主要结局为第7天NIHSS评分,按意向性治疗原则分析。
核心结论
- 作者假设酰化胃饥饿素治疗可改善接受血管内取栓的缺血性卒中患者的早期恢复和长期功能结局。
- 若酰化胃饥饿素在该人群中显示安全且可能有效,本研究可为后续3期随机试验的样本量计算提供依据。
研究设计与样本
- 研究者发起的2期随机临床试验,开放标签治疗、盲法终点评估。
- 计划纳入80例接受血管内取栓且取栓前NIHSS评分≥10分的前循环缺血性卒中患者。
- 随机分为静脉酰化胃饥饿素600µg每日两次连用5天(症状发作6小时内启动)联合标准治疗组与单纯标准治疗组。
- 主要分析为按意向性治疗原则对主要结局进行组间单一比较,主要效应变量为采用多变量线性回归估计的NIHSS评分差异校正β值。
关键数值与推荐
- 主要结局为第7天NIHSS评分,校正取栓前NIHSS及其他相关基线特征。
- 次要结局包括第3天MRI梗死体积、不良事件及90天功能恢复。
- 酰化胃饥饿素剂量为600µg每日两次静脉给药,连用5天,症状发作6小时内启动。
临床怎么用
- 原文未据此给出推荐,作者认为若酰化胃饥饿素在该人群中显示安全且可能有效,本研究可为后续3期随机试验的样本量计算提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: About half of the patients with acute ischaemic stroke treated with endovascular thrombectomy (EVT) remains dependent or dies in the first 90 days. Ghrelin is a naturally occurring hormone and mildly excitatory neurotransmitter that improved functional, histological, and cytological recovery in in vitro and in vivo ischaemia-reperfusion models. Acylated ghrelin (i.e. the bioactive form) has shown safety in a range of populations, including patients with cardiovascular or neurodegenerative disease. We hypothesise that treatment with acylated ghrelin improves early recovery and long-term functional outcome in patients with ischaemic stroke treated with EVT. METHODS: We propose an investigator-initiated, phase 2, randomised, clinical trial with open-label treatment and blinded endpoint assessment in 80 patients with anterior circulation ischaemic stroke treated with EVT and a pre-EVT National Institutes of Health Stroke Scale (NIHSS) score ≥ 10. Patients will be randomised to intravenous acylated ghrelin, 600 µg twice daily for 5 days and started within 6 h of symptom onset, in addition to standard care vs. standard care alone. The primary outcome is the NIHSS score on day 7 adjusted for pre-EVT NIHSS and other relevant baseline characteristics. Secondary outcomes include infarct size on MRI at day 3, adverse events, and functional recovery at 90 days. The primary analysis will be a single comparison between the treatment groups of the primary outcome according to the intention-to-treat principle. The primary effect variable will be the adjusted beta for the difference in NIHSS score, estimated with multi-variable linear regression analysis. DISCUSSION: If administration of acylated ghrelin is found safe and potentially effective in patients with ischaemic stroke treated with EVT, this study can inform the sample size calculation for a subsequent randomised phase 3 trial to assess efficacy. TRIAL REGISTRATION: The trial has been approved and registered on ClinicalTrials.gov (NCT05726240). The first patient has been included in November 2024.
引用
- Omes QPM, van der Veen D, Kersten CJBA, et al. MR GENTLE-multicentre randomised controlled trial of ghrelin in anterior circulation ischaemic stroke treated with endovascular thrombectomy: a phase 2 trial. Trials. 2026. PMID: 41546024. doi:10.1186/s13063-026-09426-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。